Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
2 days ago • Google News
Aclaris Therapeutics Inc (ACRS)
US$ 1.22-2.4%
Price Chart
Key Statistics
Market Cap
$ 165.67M
P/E Ratio
0.00
Revenue (TTM)
$ 17.78M
Volume
413.04K
52W High
$ 5.17
52W Low
$ 1.05
Dividend Yield
0.00%
Beta
0.39
Technicals
50-Day MA
1.5008
200-Day MA
1.9808
52 Week High
5.17
52 Week Low
1.05
About ACRS
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.
Employees
61
Headquarters
Wayne, PA
CEO
Dr. Neal S. Walker D.O., M.D.
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg